Abstract
Sodium-glucose cotransporter-2 inhibitors have a unique mechanism of action in the kidneys that causes glucosuria, which lowers plasma glucose. They are also associated with reduced body weight and BP, and a low incidence of hypoglycemia. This article reviews the pharmacologic profiles and clinical implications of canagliflozin, dapagliflozin, and empagliflozin.
MeSH terms
-
Benzhydryl Compounds / therapeutic use
-
Canagliflozin / therapeutic use
-
Diabetes Mellitus, Type 2 / drug therapy*
-
Diabetes Mellitus, Type 2 / nursing*
-
Glucosides / therapeutic use
-
Humans
-
Randomized Controlled Trials as Topic
-
Sodium-Glucose Transporter 2 Inhibitors / therapeutic use*
Substances
-
Benzhydryl Compounds
-
Glucosides
-
Sodium-Glucose Transporter 2 Inhibitors
-
Canagliflozin
-
dapagliflozin
-
empagliflozin